NCT04669587View on ClinicalTrials.gov

ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

July 26, 2021

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2024

Conditions
Estrogen Receptor-PositiveHER2-NegativeLocally Advanced Breast CancerMetastatic Breast Cancer
Interventions
DRUG

ZB716

Pharmaceutical form: capsule Route of administration: oral

DRUG

Palbociclib

Pharmaceutical form: capsule Route of administration: oral

Trial Locations (8)

10408

RECRUITING

National Cancer Center, Goyang-si

13496

RECRUITING

CHA Bundang Medical Center, CHA University, Seongnam-si

98104

RECRUITING

Swedish Cancer Institute, Seattle

02841

RECRUITING

Korea University Anam Hospital, Seoul

03181

RECRUITING

Kangbuk Samsung Hospital, Seoul

03722

RECRUITING

Severance Hospital, Yonsei University Health System, Seoul

05505

RECRUITING

Asan Medical Center, Seoul

06591

RECRUITING

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

Sponsors

Collaborators (1)

Zenopharm
All Listed Sponsors
collaborator

Zenopharm

UNKNOWN

lead

EnhancedBio USA Inc.

OTHER

NCT04669587 - ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study) | Biotech Hunter | Biotech Hunter